Aravive (NASDAQ:ARAV) Releases Earnings Results, Misses Expectations By $0.04 EPS

Aravive (NASDAQ:ARAV) posted its quarterly earnings results on Thursday. The company reported ($0.54) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.50) by ($0.04), Fidelity Earnings reports.

ARAV stock opened at $6.53 on Friday. The company has a market cap of $75.95 million, a PE ratio of -0.61 and a beta of 2.17. The business has a 50-day simple moving average of $7.03 and a 200 day simple moving average of $6.27. Aravive has a 52 week low of $3.07 and a 52 week high of $9.72. The company has a quick ratio of 11.28, a current ratio of 11.28 and a debt-to-equity ratio of 0.17.

In related news, CEO Jay Shepard sold 4,004 shares of the business’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $6.82, for a total value of $27,307.28. 39.80% of the stock is owned by insiders.

A number of research analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating on shares of Aravive in a research note on Friday. Zacks Investment Research downgraded Aravive from a “buy” rating to a “hold” rating in a research note on Thursday, October 24th. ValuEngine raised Aravive from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Finally, Piper Jaffray Companies set a $15.00 price target on Aravive and gave the company a “buy” rating in a research note on Friday, September 27th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $13.69.

About Aravive

Aravive, Inc, a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer.

See Also: Why is the ex-dividend date different from the record date?

Earnings History for Aravive (NASDAQ:ARAV)

Receive News & Ratings for Aravive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aravive and related companies with's FREE daily email newsletter.